Immunotherapy Before and After Lung Cancer Surgery Reduces Death Risk, Disease Recurrence
People with operable non-small cell lung cancers have a reduced risk of death and disease recurrence if they receive immunotherapy treatments before and after surgery instead of only before surgery, according to a new analysis by Johns Hopkins Kimmel Cancer Center investigators.
LEARN MORE
SEE ALL NEWS
Recent Posts
5 Healthy Habits That Help During Cancer Treatment
Understanding Mammogram Results
A 19-Year Fight Against Prostate Cancer Brings Man to Johns Hopkins Medicine
Scientists Advance Efforts to Create ‘Virtual Cell Lab’ As Testing Ground for Future Research with Live Cells
Ultra-Processed Foods: Q&A with 2 Dietitians
Radiation Therapy Overcomes Immunotherapy Resistance in Some Cancers
‘Power Surges’ on Cancer Cell Membranes May Fuel Progression of Disease
New Cancer Target Discovered
How surgeons build a new bladder for cancer patients like Deion Sanders